ELUTIA INC.
Close on Oct 19, 2026
- Market cap
- $36.05M
- P/E (TTM)
- 0.9
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | During market hours | $2.40M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | During market hours | $3.10M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | Before market open | $3.30M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | During market hours | $3.30M | $-0.19 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | During market hours | $6.30M | $-0.26 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | During market hours | $6.00M | $-0.21 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 3, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | During market hours | $5.90M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 7, 2024 | During market hours | – | – | – |
Press releases
Announcements Elutia filed with the SEC
Elutia Completes SimpliDerm ® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch
Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION
Acquisition or disposition completed · Regulation FD disclosure · EX-99.2 to Form 8-K
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results
Results of operations · EX-99.1 to Form 8-K
Signs Definitive Agreement to Sell SimpliDerm ® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market
Results of operations · EX-99.1 to Form 8-K
Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process
Results of operations · EX-99.1 to Form 8-K
Elutia Regains Compliance with Nasdaq Listing Requirements
Other events · EX-99.1 to Form 8-K
Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones
Results of operations · EX-99.1 to Form 8-K
Elutia Reports Third Quarter 2025 Financial
Results of operations · EX-99.1 to Form 8-K
Elutia Appoints Accomplished MedTech Veteran
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Elutia Announces Closing of BioEnvelope Business
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Elutia Announces Sale of BioEnvelope Business
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Elutia Delivers Robust Growth on the Strength
Results of operations · EX-99.1 to Form 8-K
Elutia Announces Strong First Quarter 2025 Financial
Material agreement · Results of operations · Unregistered share sale · EX-99.1 to Form 8-K
Elutia Transitions to Direct Distribution of
Agreement terminated · Regulation FD disclosure · EX-99.1 to Form 8-K
Elutia Announces Fourth Quarter and Full Year
Results of operations · EX-99.1 to Form 8-K
Elutia Announces $15.0 Million Registered Direct
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Elutia Announces Strong Third Quarter Results,
Results of operations · EX-99.1 to Form 8-K
Launch Production of EluPro ®
Results of operations · EX-99.1 to Form 8-K
Announces $13.26 Million Registered Direct Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Elutia Announces FDA Clearance of EluPro ® :
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Announces First Quarter 2024 Results: SimpliDerm ® Sales Increase 55%,
Results of operations · EX-99.1 to Form 8-K
Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM ® Clearance Decision in First Half of 2024
Results of operations · EX-99.1 to Form 8-K
11823445 9245146 4313406 4313406 4313406 http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Member 0.60 0.40 0.60 0.40 0.33 P49D 0.66 0.33 P0Y 0.66 P20D P20D P7Y P6Y6M P6Y P3Y P2Y http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent P2Y6…
Other events · EX-99.1 to Form 8-K
26% Year-Over-Year Sales Growth of Proprietary Products and Strengthened Balance Sheet in Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Elutia Completes Divestiture of Orthobiologics
Regulation FD disclosure · EX-99.1 to Form 8-K
Elutia Announces Private Placement for Proceeds
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Elutia Announces Sale of Orthobiologics Business
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Biologics Rebrands as Elutia to Reflect Strategic Focus on Drug Eluting Biomatrices
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Biologics Reports Second Quarter 2023 Financial Results - Transformation Continues to Drug-Eluting Biomatrix Company
Results of operations · EX-99.1 to Form 8-K
Voluntary Recall of Viable Bone Matrix Products
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aziyo Biologics Reports Highest Sales and Gross
Results of operations · Listing notice · EX-99.1 to Form 8-K
Aziyo Biologics and LeMaitre Vascular Partner for the Distribution of Aziyo’s Cardiovascular Portfolio
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Aziyo Biologics Reports Record Full Year 2022
Results of operations · EX-99.1 to Form 8-K
Update on FDA Submission for CanGaroo ® RM Antibacterial Envelope
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aziyo Biologics Announces Record Annual Net
Results of operations · EX-99.1 to Form 8-K
Biologics Reports Strong Third Quarter 2022 Revenue
Results of operations · EX-99.1 to Form 8-K
Co-Founder, President, CEO & Director
Results of operations · EX-99.2 to Form 8-K
Biologics Appoints Seasoned Healthcare Executive, David Colpman, to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K